Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03141021

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Malignant Peripheral Nerve Sheath Tumors Clinical Trial

Official title:
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Clinical Trial Summary

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03141021
Study type Observational [Patient Registry]
Source Washington University School of Medicine
Contact Angela Hirbe, M.D., Ph.D.
Phone (314) 362-8965
Email hirbea@wustl.edu
Status Recruiting
Phase
Start date April 28, 2017
Completion date April 30, 2053
View Details
See also
  Status Clinical Trial Phase
Completed NCT01661283 - SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Phase 2
Completed NCT03433183 - SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Phase 2
Active, not recruiting NCT02584647 - PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Phase 1/Phase 2
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Terminated NCT00427583 - Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Phase 2/Phase 3
Recruiting NCT05245500 - Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion Phase 1/Phase 2
Recruiting NCT03618381 - EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Active, not recruiting NCT04483778 - B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Recruiting NCT03611868 - A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05985161 - A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Phase 2